ChromaDex Revenue 2008-2021 | CDXC

ChromaDex revenue from 2008 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
ChromaDex Annual Revenue
(Millions of US $)
2020 $59
2019 $46
2018 $32
2017 $21
2016 $22
2015 $18
2014 $15
2013 $10
2012 $12
2011 $8
2010 $8
2009 $6
2008 $5
2007 $5
ChromaDex Quarterly Revenue
(Millions of US $)
2021-06-30 $18
2021-03-31 $15
2020-12-31 $15
2020-09-30 $14
2020-06-30 $15
2020-03-31 $14
2019-12-31 $13
2019-09-30 $12
2019-06-30 $11
2019-03-31 $10
2018-12-31 $9
2018-09-30 $8
2018-06-30 $8
2018-03-31 $7
2017-12-31 $8
2017-09-30 $6
2017-06-30 $4
2017-03-31 $3
2016-12-31 $2
2016-09-30 $4
2016-06-30 $9
2016-03-31 $7
2015-12-31 $0
2015-09-30 $6
2015-06-30 $6
2015-03-31 $5
2014-12-31 $4
2014-09-30 $4
2014-06-30 $4
2014-03-31 $3
2013-12-31 $2
2013-09-30 $3
2013-06-30 $3
2013-03-31 $2
2012-12-31 $4
2012-09-30 $4
2012-06-30 $3
2012-03-31 $2
2011-12-31 $2
2011-09-30 $2
2011-06-30 $2
2011-03-31 $3
2010-12-31 $2
2010-09-30 $2
2010-06-30 $2
2010-03-31 $2
2009-12-31 $2
2009-09-30 $1
2009-06-30 $1
2009-03-31 $1
2008-12-31 $1
2008-09-30 $1
2008-06-30 $1
2008-03-31 $1
2007-09-30 $1
2007-06-30 $1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.434B $0.059B
ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, `green`, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00